Simeprevir|TMC-435|HCV NS3/4A inhibitor|DC Chemicals

Cas No.:	923604-59-5
Synonyms:	TMC435; TMC435350; TMC-435350
SMILES:	COC1=CC=C2C(=CC(C3SC=C(C(C)C)N=3)=NC2=C1C)O[C@H]1C[C@H]2C(N(CCCCC=C[C@@H]3C[C@]3(NC(=O)[C@@H]2C1)C(NS(C1CC1)(=O)=O)=O)C)=O \|t:34,&1:22,24,33,35,39\|
Formula:	C₃₈H₄₇N₅O₇S₂
M.Wt:	749.94
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC8612	Simeprevir(TMC-435)	Simeprevir (TMC 435350) is a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM).
DC8178	Beclabuvir(BMS-791325)	non-nucleoside inhibitor of the NS5B
DC11494	INX-08189	INX-08189 is a phosphoramidate prodrug of O-6-methyl-2-C-methyl guanosine, potent inhibitor of HCV NS5B polymerase with IC50 of 10 nM in replicon assay.
DC11081	Coblopasvir	Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection..
DC11731	Ruzasvir	A potent, pan-genotype HCV NS5A inhibitor with replicon EC90 of 0.003, 0.016, 0.067, 0.036, 0.007, and 0.007 nM for GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a, and Gt4a, respectively..
DC11825	MK-8876	A novel, broadly acting non-nucleoside inhibitor of HCV NS5B polymerase with IC50 of 3 nM and 2 nM for GT1b and GT2a, respectively.
DC11823	BMS-929075	A highly potent, selective, orally bioavailable HCV NS5B polymerase inhibitor with IC50 of 9, 4, and 18 nM for GT1a, GT1b, and GT1b-C316N mutant in HCV replicon assay, respectively.

Simeprevir(TMC-435)